<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Evaluate Human-Specific TIM-3 Immunotherapeutics In Vivo

Research is currently ongoing on how to improve the low overall response rate to checkpoint inhibitors, potentially through combination with other immunotherapeutics or new checkpoint targets e.g. TIM-3. TIM-3 and PD-1 co-expression is often associated with an exhausted phenotype of tumor infiltrating lymphocytes, and TIM-3 expression has been reported as a compensatory mechanism in PD-1 non-responsive patients.